ClinicalTrials.gg
RecruitingNCT07288177RAINFOL-05Updated Nov 3, 2026

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

A Phase 2 interventional study of Rina-S in Non-small Cell Lung Cancer (NSCLC), sponsored by Genmab. Recruiting at 102 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Genmab · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Nov 3, 2026First site in South Korea28 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Carcinoma, Non-Small-Cell Lung by Genmab — 2 open to participants now, 3 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Genmab.

Planned enrollment
4th of 10
240 · median 87
Started
2026
the only one that year
Phase 2
4 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Carcinoma, Non-Small-Cell Lung by Genmab, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 4 in phase 2, and was the 11th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 11 studies in Carcinoma, Non-Small-Cell Lung by Genmab are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Carcinoma, Non-Small-Cell Lung by Genmab, or all of them as a file.
02

Study summary

This Phase 2 study will be conducted in different countries around the world with up to about 240 participants.

The purpose of this study is to evaluate how well Rina-S works against lung cancer.

The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active drug; no one will be given placebo.

The treatment duration will be different for every participant, but an average of 12 months is expected. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of cycle is 3 weeks). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.

Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective.

Read the detailed description

This is a Phase 2, open-label, multicenter, multi-cohort trial to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics of Rina-S as monotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC), with or without select genomic aberrations.

03

Conditions studied

  • Non-small Cell Lung Cancer (NSCLC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant has or cytologically confirmed or locally advanced NSCLC of adenocarcinoma histology, not amenable to curative surgery or radiotherapy.
  • Participant must have radiological disease progression while on or after receiving the most recent regimen.
  • Participants either may have actionable genetic alterations (AGAs) or no AGAs.
  • Participant has according to v1.1.
  • Participant has an (ECOG) Performance Status (PS) score of 0 or 1 within 7 days of Cycle 1 Day 1.

Key Exclusion Criteria (all study cohorts):

  • Participant has NSCLC with histology other than adenocarcinoma
  • Participant has a past or current other than the inclusion diagnosis before the planned first dose of trial treatment, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5-year OS ≥ 90%), including, but not limited to, adequately treated cervical carcinoma of stage 1B or less, in situ basal cell or squamous cell skin carcinoma, in situ bladder cancer, ductal carcinoma in situ, or any past malignancy considered cured for ≥ 3 years.
  • Participants with newly identified or known unstable (eg, progressing ) or symptomatic central nervous system (CNS) metastases or history of carcinomatous meningitis (also known as ). Participants with history of spinal cord compression (from disease). Participants with previous CNS-directed therapy (eg, radiotherapy and/or surgery) for brain metastases may participate provided lesion(s) are radiologically stable (ie, without evidence of progression) for at least 28 days by repeat imaging.

Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Rina-S

    Multiple cohorts (Cohorts A, B, C, D, and E) will receive Rina-S as monotherapy.

    Drug: Rina-S

Interventions

  • DrugRina-S

    Intravenous (IV) infusion.

    Also known as: Rinatabart Sesutecan, PRO1184, GEN1184

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Investigator

    Time frame: Approximately 3 years

Secondary outcomes

  1. Duration of Response (DOR) per RECIST v1.1 as Assessed by Investigator

    Time frame: Approximately 4 years

  2. Disease Control Rate (DCR) per RECIST v1.1 as Assessed by Investigator

    Time frame: Approximately 4 years

  3. Progression-free Survival (PFS)

    Time frame: Approximately 4 years

  4. Overall Survival (OS)

    Time frame: Approximately 4 years

  5. Maximum (Peak) Observed Serum Drug Concentration (Cmax) of Rina-S Related Analytes

    Time frame: Approximately 12 months

  6. Time to Reach Maximum (Peak) Serum Drug Concentration (Tmax) of Rina-S Related Analytes

    Time frame: Approximately 12 months

  7. Number of Participants with Antidrug Antibodies (ADAs)

    Time frame: Approximately 12 months

  8. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Approximately 4 years

07

Study locations

102 of 102 sites recruiting

Showing the first 100 of 102 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Nov 2027, 21 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 21 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 17, 2025
StartActual
Jan 30, 2026
Primary completionEst.
Nov 22, 2027
CompletionEst.
Nov 22, 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
28 sites added — first site in South Korea
Show 28 added (5 Australia, 5 South Korea, 4 Spain, 3 China, 3 Italy, 2 United States, 2 Belgium, 1 Germany, 1 Japan, 1 Netherlands, 1 Taiwan)
  • City of Hope Orange County Lennar Foundation Cancer Center · Irvine, United States
  • University of Miami Hospital · Miami, United States
  • Icon Cancer Centre Townsville ICON Cancer Care - Townsville · Hyde Park, Australia
  • Universitair Ziekenhuis Antwerpen · Edegem, Belgium
  • Jessa Ziekenhuis - Campus Virga Jesse · Hasselt, Belgium
  • Beijing Cancer Hospital · Beijing, China
  • Jilin Provincial Cancer Hospital · Changchun, China
  • Nanjing Medical University (NMU) - Jiangsu Province Hospital (First Affiliated Hospital) · Nanjing, China
  • Thoraxklinik-Heidelberg · Heidelberg, Germany
  • Azienda Ospedaliero Universitaria San Luigi Gonzaga · Orbassano, Italy
  • Ospedale Santa Maria delle Croci · Ravenna, Italy
  • Policlinico Agostino Gemelli · Roma, Italy
  • National Cancer Center - Tsukiji Campus · Chūō, Japan
  • Hospital Teresa Herrera · A Coruña, Spain
  • Hospital Universitario Insular de Gran Canaria · Las Palmas de Gran Canaria, Spain
  • Hospital General Universitario Gregorio Marañón · Madrid, Spain
  • Hospital Universitario Fundación Jiménez Díaz · Madrid, Spain
  • Blacktown Hospital · Blacktown, Australia
  • St Vincent's Hospital - Melbourne · Fitzroy, Australia
  • St George Hospital · Kogarah, Australia
  • Sir Charles Gairdner Hospital · Nedlands, Australia
  • Radboudumc · Nijmegen, Netherlands
  • Chungbuk National University Hospital · Cheongju-si, South Korea
  • Keimyung University Dongsan Hospital · Daegu, South Korea
  • Gachon University Gil Medical Center · Incheon, South Korea
  • Korea University Anam Hospital · Seoul, South Korea
  • The Catholic University Of Korea St. Vincent's Hospital · Suwon, South Korea
  • National Taiwan University Hospital (NTUH) · Taipei, Taiwan
across 2 updates, Oct 6, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    11 sites added — first site in South Korea
    Show 11 added (5 South Korea, 4 Australia, 1 Netherlands, 1 Taiwan)
    • Blacktown Hospital · Blacktown, Australia
    • St Vincent's Hospital - Melbourne · Fitzroy, Australia
    • St George Hospital · Kogarah, Australia
    • Sir Charles Gairdner Hospital · Nedlands, Australia
    • Radboudumc · Nijmegen, Netherlands
    • Chungbuk National University Hospital · Cheongju-si, South Korea
    • Keimyung University Dongsan Hospital · Daegu, South Korea
    • Gachon University Gil Medical Center · Incheon, South Korea
    • Korea University Anam Hospital · Seoul, South Korea
    • The Catholic University Of Korea St. Vincent's Hospital · Suwon, South Korea
    • National Taiwan University Hospital (NTUH) · Taipei, Taiwan
  2. Oct 6, 2026
    17 sites added
    Show 17 added (4 Spain, 3 China, 3 Italy, 2 United States, 2 Belgium, 1 Australia, 1 Germany, 1 Japan)
    • City of Hope Orange County Lennar Foundation Cancer Center · Irvine, United States
    • University of Miami Hospital · Miami, United States
    • Icon Cancer Centre Townsville ICON Cancer Care - Townsville · Hyde Park, Australia
    • Universitair Ziekenhuis Antwerpen · Edegem, Belgium
    • Jessa Ziekenhuis - Campus Virga Jesse · Hasselt, Belgium
    • Beijing Cancer Hospital · Beijing, China
    • Jilin Provincial Cancer Hospital · Changchun, China
    • Nanjing Medical University (NMU) - Jiangsu Province Hospital (First Affiliated Hospital) · Nanjing, China
    • Thoraxklinik-Heidelberg · Heidelberg, Germany
    • Azienda Ospedaliero Universitaria San Luigi Gonzaga · Orbassano, Italy
    • Ospedale Santa Maria delle Croci · Ravenna, Italy
    • Policlinico Agostino Gemelli · Roma, Italy
    • National Cancer Center - Tsukiji Campus · Chūō, Japan
    • Hospital Teresa Herrera · A Coruña, Spain
    • Hospital Universitario Insular de Gran Canaria · Las Palmas de Gran Canaria, Spain
    • Hospital General Universitario Gregorio Marañón · Madrid, Spain
    • Hospital Universitario Fundación Jiménez Díaz · Madrid, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07288177
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Jan 30, 2026
Primary completion
Nov 22, 2027 (estimated)
Completion
Nov 22, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Genmab Trial Information
Contact
clinicaltrials@genmab.com
+4570202728
Study Official
study director · Genmab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rinatabart sesutecan

Start the discussion